Progress in the treatment of a neglected infectious disease: visceral leishmaniasis

References

• Guerin PJ, Olliaro P, Sundar S, et al Visceral leishmaniasis: current status of control, diagnosis and treatment and a proposed research and development agenda. Lancet Infict Dis. 2, 494–501 (2002).
   PubMed Web of Science ®Google Scholar
• ••Comprehensive statement of currentclinical status of visceral infection and what will be needed in the future to improve management.
   Google Scholar
• Herwaldt BL. Leishmaniasis. Lancet. 54, 1191–1199 (1999).
   Google Scholar
• Murray HW. Clinical and experimental advances in treatment in visceralleishmaniasis. Antimicrob. Agents Chemother. 45,2185–2197 (2001).
   PubMed Web of Science ®Google Scholar
• ••Review of treatment in VL, primarilyfocused on experimental approaches, including immunochemotherapy.
   Google Scholar
• Murray HW. Kala-azar — progress against a neglected disease. N EngL J. Med. 347, 1793–1794 (2002).
   PubMedGoogle Scholar
• Seaman J, Mercer AJ, Sandorp E. The epidemic of visceral leishmaniasis in western Upper Nile, southern Sudan: course and impact from 1984 to 1994. Intl. EpidemioL 25,862–871 (1996).
   PubMed Web of Science ®Google Scholar
• Pintado V, Martin-Rabadan P, Rivera ML, Morneo S, Bouza E. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine (Baltimore) 80,54–73 (2001).
   PubMed Web of Science ®Google Scholar
• Ritmeijer K, Veeken H, Melaku Y, et al Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV coinfected patients have a poor outcome. Trans. R Soc. Trap. Med. Hyg. 95,668–672 (2001).
   Google Scholar
• ••First of three similar studies in Africademonstrating the usefulness of generic sodium stibogluconate.
   Google Scholar
• Berman J. Current treatment approaches to leishmaniasis. Curr. Opin. Infect. Dis. 16, 397–401 (2003).
   PubMed Web of Science ®Google Scholar
• Sundar S, More DK, Singh MK, et al Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin. Infect. Dis. 31, 1104–1106(2000).
   PubMed Web of Science ®Google Scholar
• ••Report formally documents the demise ofsodium stibogluconate as useful treatment in India's hyper-endemic region (Bihar State), while demonstrating its continued efficacy as first-line parenteral therapy in a neighboring state.
   Google Scholar
• Das VN, Ranjan A, Sinha AN, et al A randomized clinical trial of low dosage combination of pentamidine and allopurinol in the treatment of antimony unresponsive cases of visceral leishmaniasis. J. Assoc. Physicians India 49,609–613 (2001).
   PubMedGoogle Scholar
• Dietze R, Fagundes S, Brito E, et al Treatment of kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days. Trans. R Soc. Trap. Med. Hyg. 89,309–311 (1995).
   Google Scholar
• Davidson RN, di Martino L, Gradoni L, et al Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin. Infect. Dis. 22,938–943 (1996).
   PubMed Web of Science ®Google Scholar
• Sundar S, Agrawal NK, Sinha PR, Horwith GS, Murray HW Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Ann. Intern. Med 127,133–137 (1997).
   PubMed Web of Science ®Google Scholar
• Seaman J, Boer C, Wilkinson R, et al Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clin. Infect. Dis. 21, 188–193 (1995).
   PubMed Web of Science ®Google Scholar
• Gradoni L, Bryceson A, Desjeux E Treatment of Mediterranean visceral leishmaniasis. BulL World Health Organ. 73, 191–197 (1999).
   Google Scholar
• Gradoni L, Gramiccia M, Scalone A. Visceral leishmaniasis treatment, Italy. Emerg Infect. Dis. 9,1617–1620 (2003).
   PubMed Web of Science ®Google Scholar
• Chunge CN, Owate J, Pamba HO, Donno L. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans. R. Soc. Trop. Med. Hyg 84,221–225 (1990).
   PubMed Web of Science ®Google Scholar
• Seaman J, Pryce D, Sondorp H, Wilkinson R, Bryceson ADM. Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. J. Infect. Dis. 168,715–720 (1994).
   Google Scholar
• Jha TK, 011iaro P, Thakur CP, et al. Randomised controlled trial of aminosidine (paromomycin) v. sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. Br. Med. J. 61,1200–1205 (1998).
   Google Scholar
• Thakur CP, Kanyok TP, Pandey AK, et al. A prospective randomized, comparative, open-label trial of the safety and efficacy of paromyomycin (aminosidine) plus sodium stibogluconte versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. Trans. R Soc. Trap. Med. Hyg. 94,420–431 (2000).
   Google Scholar
• Sundar S, Rosenkaimer F, Makharia MK, et al. Trial of oral miltefosine for visceral leishmaniasis. Lancet 352,1821–1823 (1998).
   PubMed Web of Science ®Google Scholar
• Sundar S, Jha TK, Thakur CP, et al Oral miltefosine for Indian visceral leishmaniasis. N EngL J. Med. 347, 1739–1746 (2002).
   PubMed Web of Science ®Google Scholar
• ••Thedefining Phase III study in Indiashowing that oral miltefosine is highly active and as effective as amphotericin B therapy.
   Google Scholar
• Murray HW. Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches. Int. J. Infect. Dis. 4,158–177 (2000).
   PubMedGoogle Scholar
• Sundar S, Rai M. Advances in the treatment of leishmaniasis. Curr Opin. Infect. Dis. 15,593–598 (2002).
   PubMed Web of Science ®Google Scholar
• Veeken H, Ritmeijer K, Seaman J, Davidson R. A randomized comparison of branded sodium stibogluconate (Pentostam, Glaxo Wellcome, London, UK) and generic sodium stibogluconate for visceral leishmaniasis under field conditions in Sudan. Trap. Med. Int. Health 5, 312–317 (2002).
   Google Scholar
• Moore E, O'Flaherty, Heuvelmans H, et al. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya. Bull. World Health Organ. 79,388–393 (2001).
   PubMed Web of Science ®Google Scholar
• Syriopoulou V, Daikos GL, Theodoridou M, et al. Two doses of a lipid formulation of amphoericin B for the treatment of Mediterranean visceral leishmaniasis. Clin. Infect. Dis. 36,560–566 (2003).
   PubMed Web of Science ®Google Scholar
• ••Study results indicate that in young children with Mediterranean VL, short-course (two-day) treatment with AmBisome is highly active and cost-effective.
   Google Scholar
• Thakur CP, Singh RK, Hassan SM, Kumar R, Narain S, Kumar A. Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Trans. R Soc. Trap. Med Hyg 93, 319–323 (1999).
   Google Scholar
• •Report documents the remarkable efficacy of conventional amphotericin B treatment in Indian VL in Bihar State, a region with high-level resistance to pentavalent antimony.
   Google Scholar
• Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R. Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis — a multicenter study. Am. J. Trap. Med Hyg. 66,143–146 (2002).
   Google Scholar
• •Multicenter trial demonstrating that remarkably low doses of AmBisome given for just five days induce high cure responses in India.
   Google Scholar
• Sundar S, Mehta H, Sures AV, Singh SE, Rai M, Murray HW Amphotericin B treatment for Indian visceral leishmaniasis: conventional vs. lipid-formulations. Clin. Infect. Dis. 38,377–383 (2004).
   PubMed Web of Science ®Google Scholar
• •Only study in VL which compares responses to conventional amphotericin B to responses achieved by lipid formulations of amphotericin B.
   Google Scholar
• Gaeta GB, Maisto A, Di Caprio D, et al Efficacy of amphotericin B colloidal dispersion in the treatment of Mediterranean visceral leishmaniasis in immunocompetent adult patients. Scand J. Infect. Dis. 32, 675–677 (2000).
   PubMedGoogle Scholar
• Bekersky IRI\4, Dressler DE, Lee JW, Buell DN, Walsh TJ, Fielding. Pharmacokinetics, excretion and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimircob. Agents Chemother. 46,828–833 (2002).
   PubMed Web of Science ®Google Scholar
• Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomized trial. Br Med. J. 323,419–242 (2001).
   PubMed Web of Science ®Google Scholar
• •Study results indicated 91% cure induced in India by a single-infusion of low-dose AmBisome.
   Google Scholar
• Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin. Infect. Dis. 37,800–804 (2003).
   PubMed Web of Science ®Google Scholar
• •Report indicates the high-level efficiency of AmBisome in Indian VL, since patients were safely discharged approximately 24 h after a single infusion.
   Google Scholar
• Sundar S, Goyal AK, More DK, Singh MK, Murray HW Ultra-short-course amphotericin B lipid complex treatment for antimony-unresponsive Indian visceral leishmaniasis. Ann. Trap. Med Parasitol 92, 755–764 (1998).
   PubMed Web of Science ®Google Scholar
• Berman JD, Badaro R, Thakur CP, et al Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ. 76, 25–32 (1998).
   PubMed Web of Science ®Google Scholar
• •Results indicated that responses to treatment in VL vary by region (India > Kenya > Brazil).
   Google Scholar
• Sundar S, Gupta LB, Rastogi V, Agrawal G, Murray HW Short-course, cost-effective treatment with amphotericin B-fat emulsion cures visceral leishmaniasis. Trans. R Soc. Trap. Med Hyg. 94, 200–204 (2000).
   Google Scholar
• Bodhe PV, Kotwani RN, Kirodian BG, et al Dose-ranging studies on liposomal amphotericin B (L-AMP-LRC-1) in the treatment of visceral leishmaniasis. Trans. R Soc. Trop. Med Hyg 93, 314–318 (1999).
   PubMed Web of Science ®Google Scholar
• Pagliano P, Rossi M, Rescigno C, et al Mediterranean visceral lishmaniasis in HIV-negative adults: a retrospective analysis of 64 consecutive cases (1995-2001).j Antimicrob. Chemother. 52, 264–268 (2003).
   Google Scholar
• Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: time for a new 'gold standard'. Clin. Infect. Dis. 37, 415–425 (2003).
   PubMed Web of Science ®Google Scholar
• Yeates C. Sitamaquine. Curr. Opin. Invest. Drugs 3, 1446–1452 (2002).
   PubMedGoogle Scholar
• Sherwood J, Gachihi G, Muigai R, et al. Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis. Clin. Infect. Dis. 19, 1034–1039 (1994).
   PubMed Web of Science ®Google Scholar
• Wasunna M, Rashid JR, Nyakundi PM, et al. Sitamaquine (SB-25220, B WR6026) in the oral treatment of visceral leishmaniasis. Second World Congress on Leishmaniaisis.(2001) (Abstract 125).
   Google Scholar
• Dietze R, Carvalho SF, Muigai RK, et al. Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. Am. J. Trap. Med. Hyg. 65, 685–689 (2001).
   PubMed Web of Science ®Google Scholar
• Croft SL, Neal RA, Pendergast W, Chan JH. The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochem. Pharmacol 36, 2633–2636 (1987).
   PubMed Web of Science ®Google Scholar
• Sundar S, Sundar S, Gupta LB, et al. Oral treatment of visceral leishmaniasis with miltefosine. Ann. Trap. Med ParasitoL 93, 589–597 (1999).
   PubMed Web of Science ®Google Scholar
• Jha TK, Sundar S, Thakur CP, et al. Efficacy and toxicity of miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J. Med. 341, 1795–1800 (1999).
   PubMed Web of Science ®Google Scholar
• Sundar S, Makharia A, More DK, et al. Short-course oral miltefosine treatment for visceral leishmaniasis. Clin. Infect. Dis. 31, 1110–1103 (2000).
   PubMed Web of Science ®Google Scholar
• Sundar S, Jha TK, Sindermann H, Junge K, Bachmann P, Berman J. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. Pediatr. Infect. Dis. 22, 434–438 (2003).
   Google Scholar
• Bhattacharya SK, Jha TK, Sundar S, et al. Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Cho. Infect. Dis. 38, 217–221 (2004).
   PubMed Web of Science ®Google Scholar
• Alvar J, Canavate C, Gutierrez-Solar B, et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin. Microbial Rev. 10, 298–319 (1997).
   PubMed Web of Science ®Google Scholar
• De la Rosa R, Pineda JA, Delgado J, et al. Influence of highly active antiretroviral therapy on the outcome of subdinical visceral leishmaniasis in human immunodeficiency virus-infected patients. Clin. Infect. Dis. 32, 633–635 (2001).
   PubMed Web of Science ®Google Scholar
• Laguna F, Lopez-Velez R, Pulido F, et al. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. AIDS 13, 1063–1070 (1999).
   PubMed Web of Science ®Google Scholar
• •• Randomized controlled trial indicating that responses to both pentavalent antimony and amphotericin B are impaired in HIV-associated VL.
   Google Scholar
• Laguna F, Videla S, Jimenez-Mejias ME, et al. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study. J. Antimicrob. Chemother. 52, 464–469 (2003).
   PubMed Web of Science ®Google Scholar
• Murray HW Suppression of post-treatment recurrence of experimental visceral leishmaniasis in T-cell-deficient mice by oral miltefosine. Antimicrob. Agents Chemother. 44, 3235–3236 (2000).
   PubMedGoogle Scholar
• Fernandez-Cotarelo MJ, Abellan-Martinez JA, Guerra-Vales JM, et al. Effect of highly active antiretroviral therapy on the incidence and clinical manifestations of visceral leishmaniasis in human immunodeficiency virus-infected patients. Clin. Infect. Dis. 37, 973–977 (2003).
   PubMedGoogle Scholar
• Berenguer J, Gomez-Campdera F, Padilla B, et al Visceral leishmaniasis (kala-azar) in transplant recipients. Transplantation 65, 1401–1404 (1998).
   PubMedGoogle Scholar
• Hernandez-Perez J, Yebra-Bango M, Jimenez-Martinez E, et al Visceral leishmaniasis (kala-azar) in solid organ transplantation: report of five cases and review. Clin. InjQct. Dis. 29, 918–921 (1999).
   PubMedGoogle Scholar
• Croft SL, Yardley V Chemotherapy of leishmaniasis. Cuff. Pharm. Des. 8, 319–342 (2002).
   PubMed Web of Science ®Google Scholar
• •Comprehensive review of current and future potential treatments.
   Google Scholar
• Croft SL, Coombs GH. Leishmaniasis —current chemotherapy and recent advances in the search for novel drugs. Emu& Parasitol 19, 502–508 (2003).
   Google Scholar
• Davis AJ, Murray HW, Handman E. Drugs against leishmaniasis: a synergy of technology and partnerships. Trends Parasitol 20, 73–76 (2004).
   PubMedGoogle Scholar
• Wilson ME, Young BM, Davidson BL, Menta KA, McGowan SE. The importance of TGF-13 in murine visceral leishmaniasis. Immunol 161,6148–6155 (1998).
   Web of Science ®Google Scholar
• Murphy ML, Cotterell S, Gorak M, Engwerda CR, Kaye PM. Blockade of CTLA-4 enhances host resistance to the intracellular pathogen, Leishmania donovani. J Immunol 161, 4153–4160 (1998).
   Google Scholar
• Melby PC, Yang Y-Z, Cheng J, Zhao W Regional differences in the cellular immune response to experimental cutaneous or visceral infection with Leishmania donovani. Infect. Immun. 66, 18–27 (1998).
   PubMedGoogle Scholar
• Murray HW Tissue granuloma structure-function in experimental visceral leishmaniasis. Int. J Exp. Pathol 82,249–267 (2001).
   PubMedGoogle Scholar
• Murray, HW, Lu CM, Brooks EB, Fichtl RE, DeVecchio JL, Heinzel FP Modulation of T-cell costimulation as immuno-or immunochemotherapy in experimental visceral leishmaniasis. Infect. Immun. 71, 6453–6462 (2003).
   Google Scholar
• Awasthi A, Mathur R, Khan A, et al CD40 signaling is impaired in L. major-infected macrophages and is rescued by a p38MARK activator establishing a host-protective memory T-cell response. J Exp. Med 197,1037–1043 (2003).
   PubMed Web of Science ®Google Scholar
• Murray, HW, CM. Lu CM, S. Mauze S, et al Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect. Immun. 70, 6284–6293 (2002).
   PubMed Web of Science ®Google Scholar
• •Experimental rationale for targeting IL-10 for inhibition as a form of immunotherapy for visceral infection.
   Google Scholar
• Murray, HW, Brooks EB, DeVecchio JL, Heinzel FP Immunoenhancement combined with amphotericin B as treatment in experimental visceral leishmaniasis. Antimicrob. Agents Chemother. 47, 2513–2517 (2003).
   PubMed Web of Science ®Google Scholar
• Badaro R, Nascimento C, Carvalho J, et al Recombinant human granulocyte—macrophage colony-stimulating factor reverses neutropenia and reduces secondary infections in visceral leishmaniasis. J. Infect. Dis. 170, 413–418 (1994).
   PubMed Web of Science ®Google Scholar
• Murray HW, Moreira AL, Lu CM, et al. Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis. J. Infect. Dis. 188, 458–464 (2003).
   PubMed Web of Science ®Google Scholar
• Karp C, Wynn T, Satti M, et al In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma. J. Clin. Invest. 91, 1644–1648 (1993).
   Google Scholar
• Ghalib H, Piuvezam M, SkeilyY, et al Interleukin-10 production correlates with pathology in human Leishmania donovani infection. J. Clin. Invest. 92, 324–329 (1993).
   PubMed Web of Science ®Google Scholar
• Sundar S, Reed SG, Sharma S, Mehrota A, Murray HW. Circulating Thl cell-and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. Am. J. Trap. Med. Hyg 56, 522–526 (1997).
   Google Scholar
• Gasim A, El-Hassan A, Khalil AE, et al High levels of plasma IL-10 and expression of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of post-kala-azar dermal leishmaniasis. Clin. Exp. Immunol. 111, 64–69 (1998).
   PubMed Web of Science ®Google Scholar
• •Clinical demonstration supporting the targeting IL-10 for inhibition as a future immunotherapeutic approach in VL.
   Google Scholar
• Barcellar O, d'Oliveira A, Jeronimo S, Carvallm EM. IL-10 and IL-12 are the main regulatory cytokines in visceral leishmaniasis. Cytokine 12, 1228–1231 (2000).
   PubMedGoogle Scholar
• Murray HW interleukin-10 receptor blockade-pentavalent antimony treatment in experimental visceral leishmaniasis (submitted).
   Google Scholar